Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
NCT00467740
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
296
Enrollment
INDUSTRY
Sponsor class
Conditions
Asthma
Interventions
DRUG:
BI 1744 CL
Sponsor
Boehringer Ingelheim